GLP-1-based therapeutics for cardiorenal protection in metabolic diseases
Ellen M. Apperloo(Dialyse Centrum Groningen), Marcel H.A. Muskiet(Amsterdam University Medical Centers), Hiddo J.L. Heerspink(University Medical Center Groningen), Daniël H. van Raalte(Amsterdam University Medical Centers)
Cited by 9
Related Papers
Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy
|New England Journal of Medicine|2019|6k
Dapagliflozin in Patients with Chronic Kidney Disease
|New England Journal of Medicine|2020|5.2k
Associations of kidney disease measures with mortality and end-stage renal disease in individuals with and without diabetes: a meta-analysis
|The Lancet|2012|1.4k
Bardoxolone Methyl in Type 2 Diabetes and Stage 4 Chronic Kidney Disease
|New England Journal of Medicine|2013|990